

LETTER

Yogurt consumption and risk of conventional and serrated precursors of colorectal cancer

Davenport *et al*¹ underscored the urgent need to identify new modifiable factors for colorectal adenomas. A few studies²⁻³ reported that higher yogurt intake may reduce the risk of colorectal cancer (CRC), potentially mediated by the gut microbiome. However, no study has yet evaluated the association between yogurt intake and precursors of CRC.

We prospectively evaluated the association between yogurt intake and risk of conventional adenoma and serrated lesion, among 32 606 men in the Health Professionals Follow-up Study (HPFS) and 55 743 women in the Nurses' Health Study (NHS), who have undergone lower endoscopy between 1986 and 2012. These participants provided detailed information on demographics, lifestyle and diet including yogurt consumption every 4 years. Multivariable logistic regressions were used to calculate ORs and 95% CIs associated with cumulative average of yogurt intake. We examined the associations by adenoma type (conventional adenomas only, serrated lesions only or both), malignant potential (for conventional adenomas: high-risk (≥ 1 cm or with villous component or high grade/severe dysplasia, or ≥ 3 adenomas) vs low risk; for serrated lesions: ≥ 1 vs < 1 cm) and anatomical site (proximal, distal or rectum).

We documented 5811 adenomas in men and 8116 adenomas in women. In men, compared with individuals without yogurt consumption, men who consumed ≥ 2 servings/week had a lower risk of conventional adenoma (multivariable OR=0.81, 95% CI=0.71 to 0.94, $p_{\text{trend}}=0.01$; table 1). This inverse association was more pronounced for adenomas with high malignant potential (OR=0.74, 95% CI=0.59 to 0.92, $p_{\text{trend}}=0.01$) than those with low risk ($p_{\text{trend}}=0.25$) (figure 1A). Also, stronger inverse associations were observed for colon (OR=0.82, 95% CI=0.70 to 0.95, $p_{\text{trend}}=0.01$) than for rectal adenomas ($p_{\text{trend}}=0.95$) (figure 1B). Overall, among men, no apparent association was observed for serrated lesions ($p_{\text{trend}}=0.34$), but a trend toward inverse association for lesions ≥ 1 cm was seen (OR=0.48, 95% CI=0.25 to 0.95, $p_{\text{trend}}=0.04$) (figure 1A). In women,




Figure 1 Yogurt intake and risk of colorectal adenoma according to subtype (A); yogurt intake and risk of conventional adenoma only according to anatomical site (B) in the Health Professionals Follow-up Study (HPFS). *High-risk adenomas include adenomas ≥ 1 cm, or with tubulovillous/villous histology or high grade/severe dysplasia or ≥ 3 adenomas. OR was adjusted for the covariates denoted in table 1. P for trend was calculated using the median of each yogurt intake category as a continuous variable.

no associations were observed for conventional adenomas and/or serrated lesions (table 1) or according to adenoma subtype or anatomical sites (online supplementary table S1).

Yogurt has been recommended by the Dietary Guidelines for Americans as part of fat-free and low-fat dairy⁴; however, its intake is low. We found that yogurt intake may reduce risk of conventional adenoma, in particular those of high malignant potential, and independent of calcium and non-yogurt dairy intake. We also reported the probable inverse association with risk of large serrated lesions, an emerging clinical phenotype that also requires extensive surveillance. Taking together, yogurt may help prevent precursors of CRC, potentially through both adenoma-to-carcinoma sequence and serrated pathway. A number of possible mechanisms have been postulated. Products of the two common probiotics used in yogurt, *Lactobacillus bulgaricus* and

Streptococcus thermophilus, may reduce levels of carcinogens such as nitroreductase, faecal activated bacterial enzymes and soluble faecal bile acids.⁵⁻⁷ The stronger link between yogurt intake and colon versus rectal adenomas may in part due to the lower pH in the colon, which is more hospitable for probiotics.⁸ Yogurt may also reduce adenoma risk by exerting anti-inflammatory effects on colon mucosa and ameliorating gut barrier dysfunction.⁹ As male patients with adenoma present with increased gut permeability,¹⁰ yogurt may benefit more for men compared with women.

The strengths of the study include prospective and updated assessments of yogurt intake with large number of cases of conventional adenomas and serrated lesions. Future studies in different racial/ethnic groups are warranted to confirm these findings and elucidate underlying biological mechanisms associated with sex and anatomical site differences.

Table 1 Yogurt intake and risk of conventional adenoma and serrated lesion, HPFS and NHS 1986–2010

	Yogurt intake				P for trend*
	Never	1–3/month	1–<2/week	≥2/week	
<i>Men (HPFS)</i>					
Conventional adenomas only					
No of cases (n=3196)	1701	687	542	266	
Age-adjusted OR (95% CI)†	1 (Ref)	0.91 (0.83 to 1.00)	0.91 (0.82 to 1.00)	0.74 (0.65 to 0.84)	<0.001
Multivariable-adjusted OR (95% CI)‡	1 (Ref)	0.96 (0.87 to 1.05)	0.97 (0.87 to 1.07)	0.81 (0.71 to 0.94)	0.01
Serrated lesions only					
No of cases (n=1800)	924	392	323	161	
Age-adjusted OR (95% CI)†	1 (Ref)	0.93 (0.83 to 1.05)	0.98 (0.86 to 1.12)	0.81 (0.68 to 0.96)	0.02
Multivariable-adjusted OR (95% CI)‡	1 (Ref)	0.99 (0.88 to 1.12)	1.05 (0.92 to 1.21)	0.89 (0.74 to 1.07)	0.34
Conventional adenomas and serrated lesions					
No of cases (n=815)	439	176	138	62	
Age-adjusted OR (95% CI)†	1 (Ref)	0.90 (0.75 to 1.07)	0.87 (0.71 to 1.05)	0.66 (0.50 to 0.86)	0.001
Multivariable-adjusted OR (95% CI)‡	1 (Ref)	0.98 (0.82 to 1.18)	0.97 (0.79 to 1.18)	0.78 (0.59 to 1.04)	0.10
<i>Women (NHS)</i>					
Conventional adenomas only					
No of cases (n=3896)	1347	870	1041	638	
Age-adjusted OR (95% CI)†	1 (Ref)	1.02 (0.94 to 1.12)	1.00 (0.92 to 1.09)	0.95 (0.86 to 1.05)	0.24
Multivariable-adjusted OR (95% CI)‡	1 (Ref)	1.05 (0.96 to 1.15)	1.03 (0.94 to 1.12)	0.98 (0.88 to 1.09)	0.55
Serrated lesions only					
No of cases (n=3230)	1100	707	900	523	
Age-adjusted OR (95% CI)†	1 (Ref)	0.98 (0.89 to 1.08)	0.99 (0.90 to 1.08)	0.88 (0.79 to 0.98)	0.03
Multivariable-adjusted OR (95% CI)‡	1 (Ref)	1.03 (0.94 to 1.14)	1.02 (0.93 to 1.13)	0.92 (0.82 to 1.04)	0.14
Conventional adenomas and serrated lesions					
No of cases (n=990)	331	223	281	155	
Age-adjusted OR (95% CI)†	1 (Ref)	1.05 (0.89 to 1.25)	1.02 (0.87 to 1.20)	0.88 (0.73 to 1.07)	0.17
Multivariable-adjusted OR (95% CI)‡	1 (Ref)	1.12 (0.94 to 1.34)	1.09 (0.91 to 1.30)	0.94 (0.76 to 1.17)	0.46

*Calculated using the median of each yogurt intake category as a continuous variable.

†Adjusted for age, time period of endoscopy, number of reported endoscopies, time since most recent endoscopy and reason for current endoscopy.

‡Additionally adjusted for height (continuous), body mass index (in quintiles), family history of CRC (yes/no), diabetes (yes/no), pack-years of smoking (never, 1–4.9, 5–19.9, 20–39.9, ≥40 pack-years), alcohol intake (never, 0.1–4.9, 5–14.9, 15–29.9, ≥30 g/day), physical activity in METs (in quintiles), regular use of aspirin (yes/no), regular NSAIDs use (yes/no), total vitamin D intake (in quintiles), non-yogurt dairy intake (in quintiles), total calorie intake (in quintiles), red and processed meat intake (in quintiles), dietary fibre intake (in quintiles), total folate intake (in quintiles), Alternative Healthy Eating Index-2010 (in quintiles), total calcium intake (in quintiles), menopausal status (premenopausal/postmenopausal, NHS only) and menopausal hormone use (never/past/current, NHS only).

CRC, colorectal cancer; HPFS, Health Professionals Follow-up Study; METs, metabolic equivalent tasks; NHS, Nurses' Health Study; NSAIDs, non-steroidal anti-inflammatory drugs.

Xiaobin Zheng,^{1,2,3} Kana Wu,⁴
Mingyang Song,^{5,6,7} Shuji Ogino,^{8,9}
Charles S Fuchs,¹⁰ Andrew T Chan,^{5,6}
Edward L Giovannucci,^{4,7,8} Yin Cao,^{1,11}
Xuehong Zhang⁸

¹Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, Missouri, USA

²Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

³Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

⁴Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA

⁵Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA

⁶Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA

⁷Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA

⁸Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA

⁹Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

¹⁰Yale Cancer Center, New Haven, Connecticut, USA

¹¹Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, USA

Correspondence to Dr Yin Cao, Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine; yin.cao@wustl.edu and Dr Xuehong Zhang, Brigham and Women's Hospital and Harvard Medical School; xuehong.zhang@channing.harvard.edu

Acknowledgements We thank the participants and staff of the Nurses' Health Study and the Health Professionals Follow-up Study for their valuable contributions as well as the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY. The authors assume full responsibility for analyses and interpretation of these data. State cancer registries: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Nebraska, New Hampshire, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, Tennessee, Texas, Virginia, Washington and Wyoming.

Contributors XiZ, YC and XuZ had full access to all the data in the study and took responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: XiZ, YC, XuZ. Acquisition of data: KW, MS, ATC, ELG, YC. Analysis and interpretation of data: all coauthors. Drafting of the manuscript: XiZ, YC, XuZ. Critical revision of the manuscript for important intellectual content: all authors. Statistical analysis: XiZ, YC. Obtained funding: SO, ATC, ELG, XuZ. Administrative, technical or material support: YC, XuZ. Study supervision: YC, XuZ.

Funding Grant support: The Health Professionals Follow-up Study and Nurses' Health Study were supported by the National Institutes of Health (NIH) grants UM1CA186107, P50CA127003, P01CA87969 and UM1CA167552. This work was additional funded by NIH grants (R03 CA197879 and R21 CA222940 to KW, R21 CA230873 to KW and SO, R01 CA151993 and R35 CA197735 to SO; K24 DK098311 to ATC; K07 CA218377 to YC; K07 CA188126 to XuZ). XiZ is supported by International Programme for PhD Candidates, Sun Yat-Sen University. KW is supported by an Investigator Initiated Grants from the American Institute for Cancer Research. SO is supported by Nodal Award from the Dana-Farber Harvard Cancer Center and by grants from the Project P Fund for Colorectal Cancer Research, the Friends of the Dana-Farber Cancer Institute, Bennett Family Fund, the Entertainment

Industry Foundation through National Colorectal Cancer Research Alliance and American Association for Cancer Research (Stand Up to Cancer Colorectal Cancer Dream Team Translational Research Grant). ATC is a Stuart and Suzanne Steele MGH Research Scholar. XuZ is also supported by the American Cancer Society Research Scholar Grant (RSG NEC-130476) and Boston Nutrition Obesity Research Center Pilot and Feasibility Award.

Competing interests Charles S. Fuchs reports consulting role for Agios, Bain Capital, Bayer, Celgene, Dicerna, Five Prime Therapeutics, Gilead Sciences, Eli Lilly, Entrinsic Health, Genentech, KEW, Merck, Merrimack Pharmaceuticals, Pfizer, Sanofi, Taiho, and Unum Therapeutics. He also serves as a Director for CytomX Therapeutics and owns unexercised stock options for CytomX and Entrinsic Health.

Provenance and peer review Not commissioned; internally peer reviewed.

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/gutjnl-2019-318374>)

YC and XZ contributed equally.



To cite Zheng X, Wu K, Song M, *et al.* *Gut* Epub ahead of print: [please include Day Month Year]. doi:10.1136/gutjnl-2019-318374

Received 28 January 2019

Revised 26 April 2019

Accepted 26 April 2019

Gut 2019;**0**:1–3. doi:10.1136/gutjnl-2019-318374

REFERENCES

- 1 Davenport JR, Su T, Zhao Z, *et al.* Modifiable lifestyle factors associated with risk of sessile serrated polyps, conventional adenomas and hyperplastic polyps. *Gut* 2018;**67**:456–65.
- 2 Pala V, Sieri S, Berrino F, *et al.* Yogurt consumption and risk of colorectal cancer in the Italian European prospective investigation into cancer and nutrition cohort. *Int J Cancer* 2011;**129**:2712–9.
- 3 Murphy N, Norat T, Ferrari P, *et al.* Consumption of dairy products and colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). *PLoS One* 2013;**8**:e72715.
- 4 U.S. Department of Health and Human Services and U.S. Department of Agriculture. *Department of Agriculture. 2015 – 2020 Dietary Guidelines for Americans*. 8th Edn, 2015.
- 5 de Moreno de Leblanc A, Perdigón G. Yogurt feeding inhibits promotion and progression of experimental colorectal cancer. *Med Sci Monit* 2004;**10**:Br96–104.
- 6 Tavan E, Cayuela C, Antoine JM, *et al.* Effects of dairy products on heterocyclic aromatic amine-induced rat colon carcinogenesis. *Carcinogenesis* 2002;**23**:477–83.
- 7 Abdelali H, Cassand P, Soussotte V, *et al.* Effect of dairy products on initiation of precursor lesions of colon cancer in rats. *Nutr Cancer* 1995;**24**:121–32.
- 8 den Besten G, van Eunen K, Groen AK, *et al.* The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. *J Lipid Res* 2013;**54**:2325–40.
- 9 Gobatto N, Rachid M, Perdigón G. Anti-inflammatory effect of yoghurt in an experimental inflammatory bowel disease in mouse. *J Dairy Res* 2008;**75**:497–504.
- 10 Yang B, Bostick RM, Tran HQ, *et al.* Circulating Biomarkers of Gut Barrier Function: Correlates and Nonresponse to Calcium Supplementation among Colon Adenoma Patients. *Cancer Epidemiol Biomarkers Prev* 2016;**25**:318–26.